Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.66 |
| ▸ | IGF2R | P11717 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.35 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197757 | 1.00 | TLR4 (0.66) | TLR4IGF2RLPAR3LPAR1LPAR2 | |
| SCHEMBL4197763 | 0.96 | TLR4 (0.61) | TLR4LPAR3LPAR1LPAR2ENPP2 | |
| SCHEMBL4191939 | 0.94 | TLR4 (0.65) | TLR4NR5A2NR5A1ENPP2 | |
| SCHEMBL4194001 | 0.91 | TLR4 (0.67) | TLR4NR5A2NR5A1TNF | |
| SCHEMBL4191946 | 0.90 | TLR4 (0.60) | TLR4NR5A2NR5A1ENPP2 | |
| SCHEMBL4203419 | 0.89 | TLR4 (0.57) | TLR4NR5A2NR5A1TNF | |
| SCHEMBL4197308 | 0.89 | TLR4 (0.57) | TLR4NR5A2NR5A1TNF | |
| SCHEMBL4192270 | 0.85 | TLR4 (0.80) | TLR4 | |
| SCHEMBL4209740 | 0.85 | TLR4 (0.69) | TLR4NR5A2NR5A1ENPP2 | |
| SCHEMBL4209734 | 0.85 | TLR4 (0.69) | TLR4NR5A2NR5A1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | claimed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | claimed |
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | TLR4 294/4885IGF2R 488/4885LPAR3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.